Skip to main content

Articles

Page 1 of 79

  1. Despite significant progress in the prognosis of pediatric T-cell acute lymphoblastic leukemia (T-ALL) in recent decades, a notable portion of children still confronts challenges such as treatment resistance a...

    Authors: Yan Li, Zimu Zhang, Juanjuan Yu, Hongli Yin, Xinran Chu, Haibo Cao, Yanfang Tao, Yongping Zhang, Zhiheng Li, Shuiyan Wu, Yizhou Hu, Frank Zhu, Jizhao Gao, Xiaodong Wang, Bi Zhou, Wanyan Jiao…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:283
  2. Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma, with embryonal (ERMS) and alveolar (ARMS) representing the two most common histological subtypes. ARMS shows poor prognosis, being often...

    Authors: Virginia Di Paolo, Alessandro Paolini, Angela Galardi, Patrizia Gasparini, Loris De Cecco, Marta Colletti, Silvia Lampis, Salvatore Raieli, Cristiano De Stefanis, Evelina Miele, Ida Russo, Valentina Di Ruscio, Michela Casanova, Rita Alaggio, Andrea Masotti, Giuseppe Maria Milano…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:282
  3. The tumor microenvironment (TME) is a dynamic system orchestrated by intricate cell-to-cell crosstalk. Specifically, macrophages within the TME play a crucial role in driving tumor progression. Exosomes are ke...

    Authors: Yahang Liang, Junyu Li, Yuli Yuan, Houqiong Ju, Hualin Liao, Mingming Li, Yang Liu, Yao Yao, Lingling Yang, Taiyuan Li and Xiong Lei
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:281
  4. Lipid metabolism dysregulation is a key characteristic of hepatocellular carcinoma (HCC) onset and progression. Elevated expression of immunoglobulin (Ig), especially the Igκ free light chain with a unique Vκ4...

    Authors: Jingjing Guo, Huining Gu, Sha Yin, Jiongming Yang, Qianqian Wang, Weiyan Xu, Yifan Wang, Shenghua Zhang, Xiaofeng Liu, Xunde Xian, Xiaoyan Qiu and Jing Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:280
  5. Authors: Junsheng Chen, Da Wang, Guanhua Wu, Fei Xiong, Wenzheng Liu, Qi Wang, Yiyang Kuai, Wenhua Huang, Yongqiang Qi, Bing Wang and Yongjun Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:279

    The original article was published in Journal of Experimental & Clinical Cancer Research 2024 43:260

  6. N4-Acetylcytidine (ac4C), a highly conserved post-transcriptional mechanism, plays a pivotal role in RNA modification and tumor progression. However, the molecular mechanism by which ac4C modification mediates...

    Authors: Guozheng Li, Xin Ma, Shiyao Sui, Yihai Chen, Hui Li, Lei Liu, Xin Zhang, Lei Zhang, Yi Hao, Zihan Yang, Shuai Yang, Xu He, Qin Wang, Weiyang Tao and Shouping Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:278
  7. Early dissemination to distant organs accounts for the dismal prognosis of patients with pancreatic ductal adenocarcinoma (PDAC). Chronic, dysregulated, persistent and unresolved inflammation provides a prefer...

    Authors: Jinxin Tao, Yani Gu, Zeyu Zhang, Guihu Weng, Yueze Liu, Jie Ren, Yanan Shi, Jiangdong Qiu, Yuanyang Wang, Dan Su, Ruobing Wang, Yifan Fu, Tao Liu, Liyuan Ye, Wenhao Luo, Hao Chen…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:277
  8. In order for cancers to progress, they must evade elimination by CD8 T cells or other immune mechanisms. CD8 T cells recognize and kill tumor cells that display immunogenic tumor peptides bound to MHC I molecu...

    Authors: G. Sari, K. Dhatchinamoorthy, L. Orellano-Ariza, L. M. Ferreira, M. A. Brehm and K. Rock
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:276
  9. The vast majority of pancreatic cancers have been shown to be insensitive to single-agent immunotherapy. Exploring the mechanisms of immune resistance and implementing combination therapeutic strategies are cr...

    Authors: Weiwei Yuan, Qiyue Zhang, Yuhan Zhao, Wentao Xia, Shilin Yin, Xueyi Liang, Taoyu Chen, Gaofeng Li, Yanshen Liu, Zhiqiang Liu and Jinxi Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:275
  10. Somatic copy number alterations (SCNAs) are pivotal in cancer progression and patient prognosis. Dysregulated long non-coding RNAs (lncRNAs), modulated by SCNAs, significantly impact tumorigenesis, including c...

    Authors: Zaozao Wang, Haibo Han, Chenghai Zhang, Chenxin Wu, Jiabo Di, Pu Xing, Xiaowen Qiao, Kai Weng, Hao Hao, Xinying Yang, Yifan Hou, Beihai Jiang and Xiangqian Su
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:274
  11. The dynamics of mitochondrial respiratory cristae (MRC) and its impact on oxidative phosphorylation (OXPHOS) play a crucial role in driving the progression of high-grade glioma (HGG). However, the underlying m...

    Authors: Xiaodong Li, Jingjing Tie, Yuze Sun, Chengrong Gong, Shizhou Deng, Xiyu Chen, Shujiao Li, Yaoliang Wang, Zhenhua Wang, Feifei Wu, Hui Liu, Yousheng Wu, Guopeng Zhang, Qingdong Guo, Yanling Yang and Yayun Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:273
  12. Cholangiocarcinoma (CCA) is a highly malignant, rapidly progressing tumor of the bile duct. Owing to its chemoresistance, it always has an extremely poor prognosis. Therefore, detailed elucidation of the mecha...

    Authors: Da Wang, Junsheng Chen, Guanhua Wu, Fei Xiong, Wenzheng Liu, Qi Wang, Yiyang Kuai, Wenhua Huang, Yongqiang Qi, Bing Wang, Ruizhi He and Yongjun Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:272
  13. Pancreatic ductal adenocarcinoma tumors exhibit resistance to chemotherapy, targeted therapies, and even immunotherapy. Dendritic cells use glucose to support their effector functions and play a key role in an...

    Authors: Bo Zhang, Kenoki Ohuchida, Chikanori Tsutsumi, Yuki Shimada, Yuki Mochida, Koki Oyama, Chika Iwamoto, Nan Sheng, Shuang Fei, Koji Shindo, Naoki Ikenaga, Kohei Nakata, Yoshinao Oda and Masafumi Nakamura
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:271
  14. The role of Mediator complex subunit 1 (MED1), a pivotal transcriptional coactivator implicated in diverse biological pathways, remains unexplored in the context of oral squamous cell carcinoma (OSCC). This st...

    Authors: Zhe Li, Mengke Sun, Ruimeng Yang, Zheng Wang, Qianyu Zhu, Yue Zhang, Haosun Yang, Zhaosong Meng, Lizhi Hu and Lei Sui
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:270
  15. The mutations of oncogenic epidermal growth factor receptor (EGFR) is an important cause of lung adenocarcinoma (LUAD) malignance. It has been knowm that metabolic reprogramming is an important hallmark of mal...

    Authors: Pengyu Geng, Fei Ye, Peng Dou, Chunxiu Hu, Jiarui He, Jinhui Zhao, Qi Li, Miao Bao, Xiangnan Li, Xinyu Liu and Guowang Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:269
  16. Metabolic reprogramming plays a pivotal role in tumorigenesis and development of lung adenocarcinoma (LUAD). However, the precise mechanisms and potential targets for metabolic reprogramming in LUAD remain elu...

    Authors: Xingzhao Ji, Tianyi Zhang, Jian Sun, Xiaojia Song, Guoyuan Ma, Li Xu, Xueru Cao, yongjian jing, Fuyuan Xue, Weiying Zhang, Shengnan Sun, Qiang Wan and Yi Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:268
  17. Long noncoding RNAs (lncRNAs) are widely involved in cancer development and progression, but the functions of most lncRNAs have not yet been elucidated. Metastasis is the main factor restricting the therapeuti...

    Authors: Nan Lu, Qiming Jiang, Tianshu Xu, Qiyuan Gao, Yuepeng Wang, Zixian Huang, Zhiquan Huang and Xiaoding Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:267
  18. Vigorous CD8+ T cells play a crucial role in recognizing tumor cells and combating solid tumors. How T cells efficiently recognize and target tumor antigens, and how they maintain the activity in the “rejection” ...

    Authors: Zhouchi Yao, Yayun Zeng, Cheng Liu, Huimin Jin, Hong Wang, Yue Zhang, Chengming Ding, Guodong Chen and Daichao Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:266
  19. Pancreatic ductal adenocarcinoma (PDAC) features KRAS mutations in approximately 90% of human cases and excessive stromal response, termed desmoplastic reaction. Oncogenic KRAS drives pancreatic carcinogenesis...

    Authors: Silvia Sozzi, Isabella Manni, Cristiana Ercolani, Maria Grazia Diodoro, Armando Bartolazzi, Francesco Spallotta, Giulia Piaggio, Laura Monteonofrio, Silvia Soddu, Cinzia Rinaldo and Davide Valente
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:265
  20. There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse a...

    Authors: Carlos Casas-Arozamena, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Eva Diaz, Sara S Oltra, Cristian Pablo Moiola, Silvia Cabrera, Alexandra Cortegoso, Teresa Curiel, Alicia Abalo, Mónica Pamies Serrano, Santiago Domingo, Pablo Padilla-Iserte, Marta Arnaez de la Cruz…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:264
  21. Macrophage-based cell therapies have shown modest success in clinical trials, which can be attributed to their phenotypic plasticity, where transplanted macrophages get reprogrammed towards a pro-tumor phenoty...

    Authors: Satish kumar Reddy Noonepalle, Maria Gracia-Hernandez, Nima Aghdam, Michael Berrigan, Hawa Coulibaly, Xintang Li, Christian Zevallos-Delgado, Andrew Pletcher, Bryan Weselman, Erica Palmer, Tessa Knox, Eduardo Sotomayor, Katherine B. Chiappinelli, Duncan Wardrop, Anelia Horvath, Brett A. Shook…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:263
  22. For angioimmunoblastic T cell lymphoma (AITL), a rare cancer, no specific treatments are available and survival outcome is poor. We previously developed a murine model for AITL that mimics closely human diseas...

    Authors: Adrien Krug, Aymen Saidane, Chiara Martinello, Floriane Fusil, Alexander Michels, Christian J. Buchholz, Jean-Ehrland Ricci and Els Verhoeyen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:262
  23. Long-term accumulation of misfolded proteins leads to endoplasmic reticulum (ER) stress in colorectal cancer (CRC). However, the precise pathways controlling the decision between survival and apoptosis in CRC ...

    Authors: Yang Chen, Hengyang Shen, Zhenling Wang, Changzhi Huang, Hongqiang Zhang, Yu Shao, Ying Tong, Lei Xu, Yunfei Lu and Zan Fu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:261
  24. Cholangiocarcinoma (CCA) is a highly malignant tumor characterized by a lack of effective targeted therapeutic strategies. The protein UHRF1 plays a pivotal role in the preservation of DNA methylation and work...

    Authors: Junsheng Chen, Da Wang, Guanhua Wu, Fei Xiong, Wenzheng Liu, Qi Wang, Yiyang Kuai, Wenhua Huang, Yongqiang Qi, Bing Wang and Yongjun Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:260

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:279

  25. Patient-derived organoids (PDOs) established from tissues from various tumor types gave the foundation of ex vivo models to screen and/or validate the activity of many cancer drug candidates. Due to their phen...

    Authors: Valentin Benboubker, George M. Ramzy, Sacha Jacobs and Patrycja Nowak-Sliwinska
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:259
  26. Tumor-associated neutrophils (TANs) constitute an abundant component among tumor-infiltrating immune cells and have recently emerged as a critical player in pancreatic ductal adenocarcinoma (PDAC) progression....

    Authors: Haizhen Luo, Naoki Ikenaga, Kohei Nakata, Nobuhiro Higashijima, Pingshan Zhong, Akihiro Kubo, Chenyi Wu, Chikanori Tsutsumi, Yuki Shimada, Masataka Hayashi, Koki Oyama, Satomi Date, Toshiya Abe, Noboru Ideno, Chika Iwamoto, Koji Shindo…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:258
  27. Authors: Jessica Wagner, C. Leah Kline, Lanlan Zhou, Vladimir Khazak and Wafik S. El-Deiry
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:257

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:11

  28. Authors: Kewen He, Nahum Puebla-Osorio, Hampartsoum B. Barsoumian, Duygu Sezen, Zahid Rafq, Thomas S. Riad, Yun Hu, Ailing Huang, Tifany A. Voss, Claudia S. Kettlun Leyton, Lily Jae Schuda, Ethan Hsu, Joshua Heiber, Maria-Angelica Cortez and James W. Welsh
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:256

    The original article was published in Journal of Experimental & Clinical Cancer Research 2024 43:251

  29. Intrahepatic cholangiocarcinoma (iCCA) is one of the most lethal malignancies and highly heterogeneous. We thus aimed to identify and characterize iCCA cell subpopulations with severe malignant features.

    Authors: Yongzhi Zhao, Shuting Xue, Danduo Wei, Jianjuan Zhang, Nachuan Zhang, Liping Mao, Niya Liu, Lei Zhao, Jianing Yan, Yifan Wang, Xiujun Cai, Saiyong Zhu, Stephanie Roessler and Junfang Ji
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:255
  30. Cholesterol homeostasis is essential for healthy mammalian cells and dysregulation of cholesterol metabolism contributes to the pathogenesis of various diseases including cancer. Cancer cells are dependent on ...

    Authors: Anna Røssberg Lauridsen, Aikaterini Skorda, Nuggi Ingholt Winther, Marie Lund Bay and Tuula Kallunki
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:254
  31. Intrahepatic cholangiocarcinoma (iCCA) is a lethal primary liver tumor characterized by clinical aggressiveness, poor prognosis, and scarce therapeutic possibilities. Therefore, new treatments are urgently nee...

    Authors: Antonio Cigliano, Isabella Gigante, Marina Serra, Gianpaolo Vidili, Maria M. Simile, Sara Steinmann, Francesco Urigo, Eleonora Cossu, Giovanni M. Pes, Maria P. Dore, Silvia Ribback, Egle P. Milia, Elena Pizzuto, Serena Mancarella, Li Che, Rosa M. Pascale…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:253
  32. Glioblastoma (GBM) is an immunosuppressive, universally lethal cancer driven by glioblastoma stem cells (GSCs). The interplay between GSCs and immunosuppressive microglia plays crucial roles in promoting the m...

    Authors: Hao Wang, Lin Yao, Jinming Chen, Yanyan Li, Zuopeng Su, Yongsheng Liu, Wen Li, Yun Xiong, Heyang Gao, Xiao Zhang and Youxin Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:252
  33. Combining interleukin-2 (IL-2) with radiotherapy (RT) and immune checkpoint blockade (ICB) has emerged as a promising approach to address ICB resistance. However, conventional IL-2 cytokine therapy faces const...

    Authors: Kewen He, Nahum Puebla-Osorio, Hampartsoum B. Barsoumian, Duygu Sezen, Zahid Rafiq, Thomas S. Riad, Yun Hu, Ailing Huang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Lily Jae Schuda, Ethan Hsu, Joshua Heiber, Maria-Angelica Cortez and James W. Welsh
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:251

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:256

  34. Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of earl...

    Authors: Kim-Lea Reese, Klaus Pantel and Daniel J. Smit
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:250
  35. Breast cancer is the most prevalent cancer in women globally. Over-activated estrogen receptor (ER) α signaling is considered the main factor in luminal breast cancers, which can be effectively managed with se...

    Authors: Ting Zhuang, Shuqing Zhang, Dongyi Liu, Zhongbo Li, Xin Li, Jiaoyan Li, Penghe Yang, Chenmiao Zhang, Jiayao Cui, Mingxi Fu, Fangyu Shen, Lei Yuan, Zhao Zhang, Peng Su, Jian Zhu and Huijie Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:249
  36. High expression of ubiquitin ligase MDM2 is a primary cause of p53 inactivation in many tumors, making it a promising therapeutic target. However, MDM2 inhibitors have failed in clinical trials due to p53-indu...

    Authors: Wei Chen, Kai-Bin Yang, Yuan-Zhe Zhang, Zai-Shan Lin, Jin-Wei Chen, Si-Fan Qi, Chen-Fei Wu, Gong-Kan Feng, Da-Jun Yang, Ming Chen, Xiao-Feng Zhu and Xuan Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:248
  37. Camptothecin (CPT) is one of the frequently used small chemotherapy drugs for treating hepatocellular carcinoma (HCC), but its clinical application is limited due to severe toxicities and acquired resistance. ...

    Authors: Jing Rong, Tongtong Liu, Xiujuan Yin, Min Shao, Kun Zhu, Bin Li, Shiqi Wang, Yujie Zhu, Saisai Zhang, Likang Yin, Qi Liu, Xiao Wang and Lei Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:247
  38. Sorafenib is widely used in treating advanced hepatocellular carcinoma (HCC). However, its effectiveness in prolonging patient survival is limited by the development of drug resistance. To systematically inves...

    Authors: Huihui Zhu, Qiuhong Liu, Qinna Meng, Lingjian Zhang, Siwei Ju, Jiaheng Lang, Danhua Zhu, Yongxia Chen, Nadire Aishan, Xiaoxi Ouyang, Sainan Zhang, Lidan Jin, Lanlan Xiao, Linbo Wang, Lanjuan Li and Feiyang Ji
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:245
  39. Authors: Muhlis Akman, Ciro Monteleone, Gabriella Doronzo, Martina Godel, Francesca Napoli, Alessandra Merlini, Virginia Campani, Valeria Nele, Elisa Balmas, Tatiana Chontorotzea, Simona Fontana, Sabrina Digiovanni, Francesca Alice Barbu, Elena Astanina, Niloufar Jafari, Iris Chiara Salaroglio…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:244

    The original article was published in Journal of Experimental & Clinical Cancer Research 2024 43:219

  40. Authors: Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi and Laura Cerchia
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:243

    The original article was published in Journal of Experimental & Clinical Cancer Research 2024 43:92

  41. Renal cell carcinoma (RCC) is one of the most common tumors that afflicts the urinary system, accounting for 90–95% of kidney cancer cases. Although its incidence has increased over the past decades, its patho...

    Authors: Han Liu, Zongwei Lv, Gong Zhang, Zhenhong Yan, Song Bai, Dan Dong and Kefeng Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:242
  42. Factors to accurately stratify patients with early-stage non-small cell lung cancer (NSCLC) in different prognostic groups are still needed. This study aims to investigate 1) the prognostic potential of circul...

    Authors: Elisabetta Petracci, Luigi Pasini, Milena Urbini, Enriqueta Felip, Franco Stella, Fabio Davoli, Maurizio Salvi, Michele Beau-Faller, Michela Tebaldi, Irene Azzali, Matteo Canale, Piergiorgio Solli, Giulia Lai, Ramon Amat, Caterina Carbonell, Pierre-Emmanuel Falcoz…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:241
  43. Circulating Tumor Cells (CTCs) may serve as a non-invasive source of tumor material to investigate an individual’s disease in real-time. The Parsortix® PC1 System, the first FDA-cleared medical device for the cap...

    Authors: Mariacristina Ciccioli, Kyukwang Kim, Negar Khazan , Joseph D Khoury, Martin J Cooke, M Craig Miller, Daniel J O’Shannessy, Anne-Sophie Pailhes-Jimenez and Richard G Moore
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:240
  44. Oral squamous cell carcinoma (OSCC) accounts for around 90% of all oral cancers and is the eighth most common cancer worldwide. Despite progress in managing OSCC, the overall prognosis remains poor, with a sur...

    Authors: Ishita Gupta, Fariba Badrzadeh, Yuri Tsentalovich and Daria A. Gaykalova
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:239
  45. Neoadjuvant therapy improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma. However, accurately predicting individual recurrence risk remains a significant challenge. We investigate...

    Authors: Wei Yen Chan, Jenny H. Lee, Ashleigh Stewart, Russell J. Diefenbach, Maria Gonzalez, Alexander M. Menzies, Christian Blank, Richard A. Scolyer, Georgina V. Long and Helen Rizos
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:238
  46. Activator protein-1 (AP-1) represents a transcription factor family that has garnered growing attention for its extensive involvement in tumor biology. However, the roles of the AP-1 family in the evolution of...

    Authors: Hongchao Zhang, Guopei Zhang, Mingyang Xiao, Su Cui, Cuihong Jin, Jinghua Yang, Shengwen Wu and Xiaobo Lu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:237
  47. Anti-HER2 therapies, including the HER2 antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have led to improved survival outcomes in patients with HER2-overexpres...

    Authors: Jangsoon Lee, Kumiko Kida, Jiwon Koh, Huey Liu, Ganiraju C. Manyam, Young Jin Gi, Dileep R. Rampa, Asha S. Multani, Jing Wang, Gitanjali Jayachandran, Dae-Won Lee, James M. Reuben, Aysegul Sahin, Lei Huo, Debu Tripathy, Seock-Ah Im…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:236
  48. Ubiquitin-specific protease 15 (USP15) exhibits amplifications in various tumors, including gastric cancer (GC), yet its biological function and mechanisms in GC progression remain elusive.

    Authors: Longtao Huangfu, Huanbo Zhu, Gangjian Wang, Junbing Chen, Yongqi Wang, Biao Fan, Xiaoyang Wang, Qian Yao, Ting Guo, Jing Han, Ying Hu, Hong Du, Xiaomei Li, Jiafu Ji and Xiaofang Xing
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:235
  49. Betel quid and its major ingredient, areca nut, are recognized by IARC as major risk factors in oral cancer development. Areca nut extract (ANE) exposure has been linked to OPMD progression and malignant trans...

    Authors: Shyng-Shiou F. Yuan, Leong-Perng Chan, Hieu D. H. Nguyen, Chang-Wei Su, Yuk-Kwan Chen, Jeff Yi-Fu Chen, Shigetaka Shimodaira, Stephen Chu‐Sung Hu, Steven Lo and Yen-Yun Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:233

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 11.4
    5-year Journal Impact Factor: 11.4
    Source Normalized Impact per Paper (SNIP): 1.770
    SCImago Journal Rank (SJR): 2.806

    Speed 2023
    Submission to first editorial decision (median days): 5
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 3,003,080
    Altmetric mentions: 3,022